Towards evidence-based response criteria for cancer immunotherapy

Elena Garralda; Scott A Laurie; Lesley Seymour; Elisabeth G E de Vries

doi:10.1038/s41467-023-38837-3

Towards evidence-based response criteria for cancer immunotherapy

Elena Garralda, Scott A Laurie, Lesley Seymour, Elisabeth G E de Vries^*

^*Corresponding author voor dit werk

Onderzoeksoutput: Article › Academic › peer review

15 Citaten (Scopus)

73 Downloads (Pure)

Samenvatting

Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.

Originele taal-2	English
Artikelnummer	3001
Aantal pagina's	4
Tijdschrift	Nature Communications
Volume	14
DOI's	https://doi.org/10.1038/s41467-023-38837-3
Status	Published - 24-mei-2023

Toegang tot document

10.1038/s41467-023-38837-3Licentie: CC BY

Towards evidence-based response criteria for cancer immunotherapyFinal publisher's version, 587 KBLicentie: CC BY

Handle.net

Permanente koppeling

Citeer dit

@article{b16ac6321c5240699641ed560cf17242,

title = "Towards evidence-based response criteria for cancer immunotherapy",

abstract = "Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.",

keywords = "Humans, Neoplasms/therapy, Immunotherapy",

author = "Elena Garralda and Laurie, \{Scott A\} and Lesley Seymour and \{de Vries\}, \{Elisabeth G E\}",

year = "2023",

month = may,

day = "24",

doi = "10.1038/s41467-023-38837-3",

language = "English",

volume = "14",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Towards evidence-based response criteria for cancer immunotherapy

AU - Garralda, Elena

AU - Laurie, Scott A

AU - Seymour, Lesley

AU - de Vries, Elisabeth G E

PY - 2023/5/24

Y1 - 2023/5/24

N2 - Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.

AB - Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.

KW - Humans

KW - Neoplasms/therapy

KW - Immunotherapy

U2 - 10.1038/s41467-023-38837-3

DO - 10.1038/s41467-023-38837-3

M3 - Article

C2 - 37225715

SN - 2041-1723

VL - 14

JO - Nature Communications

JF - Nature Communications

M1 - 3001

ER -

Towards evidence-based response criteria for cancer immunotherapy

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit